B Klump

Summary

Country: Germany

Publications

  1. ncbi Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature
    B Klump
    Department of Internal Medicine I, University Hospital, Otfried Muller Strasse 10, 72076, Tubingen, Germany
    Int J Colorectal Dis 19:23-42. 2004
  2. ncbi Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease
    Bodo Klump
    Department of Internal Medicine I, University Hospital of Tubingen, Germany
    Clin Cancer Res 9:1773-8. 2003
  3. pmc Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions
    B Klump
    Department of Internal Medicine I, University Hospital Tubingen, Germany
    Br J Cancer 88:217-22. 2003
  4. pmc Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX
    O Nehls
    Department of Internal Medicine I, University Hospital, Tubingen, Germany
    Br J Cancer 96:1409-18. 2007
  5. ncbi Sarcoidosis mimicking cholangiocarcinoma
    O Nehls
    Department of Gastroenterology, Hepatology and Infectious Diseases, Internal Medicine I, University Hospital, Tuebingen, Germany
    Endoscopy 38:E65-6. 2006
  6. pmc Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
    O Nehls
    Department of Internal Medicine I, University Hospital, Tubingen, Germany
    Br J Cancer 98:309-15. 2008
  7. pmc Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
    O Nehls
    Department of Internal Medicine I, University Hospital, Otfried Muller Str 10, 72076 Tubingen, Germany
    Br J Cancer 87:702-4. 2002
  8. ncbi Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance
    K Holzmann
    Department of Internal Medicine I, , , Germany
    Dis Colon Rectum 44:1446-55. 2001
  9. ncbi [Malabsorption syndrome. Rare differential diagnosis in a young patient]
    M Bitzer
    Abteilung Innere Medizin I, Medizinische Universitätsklinik Tübingen
    Internist (Berl) 45:211-5. 2004
  10. ncbi Questions on life satisfaction (FLZM) in inflammatory bowel disease
    K H Janke
    Competence Network IBD Core Facility Tübingen, Department of Internal Medicine I, University Hospital Tubingen, Otfried Muller Strasse 10, 72076 Tubingen, Germany
    Int J Colorectal Dis 19:343-53. 2004

Collaborators

Detail Information

Publications21

  1. ncbi Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature
    B Klump
    Department of Internal Medicine I, University Hospital, Otfried Muller Strasse 10, 72076, Tubingen, Germany
    Int J Colorectal Dis 19:23-42. 2004
    ....
  2. ncbi Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease
    Bodo Klump
    Department of Internal Medicine I, University Hospital of Tubingen, Germany
    Clin Cancer Res 9:1773-8. 2003
    ..The INK4a/ADP ribosylation factor (ARF) locus encodes two tumor suppressor genes: p16INK4a and p14ARF. p16INK4a has been shown to be of major significance in cholangiocarcinoma...
  3. pmc Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions
    B Klump
    Department of Internal Medicine I, University Hospital Tubingen, Germany
    Br J Cancer 88:217-22. 2003
    ..Our data further indicate a potential role for INK4a methylation as a diagnostic marker in the endoscopic differentiation of benign and malignant pancreatic disease...
  4. pmc Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX
    O Nehls
    Department of Internal Medicine I, University Hospital, Tubingen, Germany
    Br J Cancer 96:1409-18. 2007
    ..BAX protein expression may be of central significance for clinical outcome to 5-FU-based adjuvant chemotherapy in stage III colon cancer, and bivariate analysis of p53/BAX possibly may provide further prognostic evidence...
  5. ncbi Sarcoidosis mimicking cholangiocarcinoma
    O Nehls
    Department of Gastroenterology, Hepatology and Infectious Diseases, Internal Medicine I, University Hospital, Tuebingen, Germany
    Endoscopy 38:E65-6. 2006
  6. pmc Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
    O Nehls
    Department of Internal Medicine I, University Hospital, Tubingen, Germany
    Br J Cancer 98:309-15. 2008
    ..Our data suggest that the CAPOX regimen is a well-tolerated and active treatment option for advanced ECC and GBC but might produce poorer results for ICC...
  7. pmc Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
    O Nehls
    Department of Internal Medicine I, University Hospital, Otfried Muller Str 10, 72076 Tubingen, Germany
    Br J Cancer 87:702-4. 2002
    ..5 months (range 0.9-26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary...
  8. ncbi Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance
    K Holzmann
    Department of Internal Medicine I, , , Germany
    Dis Colon Rectum 44:1446-55. 2001
    ..Primary sclerosing cholangitis represents an additional risk factor for the development of DNA aneuploidy and dysplasia...
  9. ncbi [Malabsorption syndrome. Rare differential diagnosis in a young patient]
    M Bitzer
    Abteilung Innere Medizin I, Medizinische Universitätsklinik Tübingen
    Internist (Berl) 45:211-5. 2004
    ..After discontinuation of the antibiotic therapy the patient reached a sustained response...
  10. ncbi Questions on life satisfaction (FLZM) in inflammatory bowel disease
    K H Janke
    Competence Network IBD Core Facility Tübingen, Department of Internal Medicine I, University Hospital Tubingen, Otfried Muller Strasse 10, 72076 Tubingen, Germany
    Int J Colorectal Dis 19:343-53. 2004
    ..This study examined QOL in IBD outpatients and the contribution of individual expectations and various other factors including disease activity...
  11. ncbi Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis
    K Holzmann
    Department of Gastroenterology, University of Tubingen, Germany
    Int J Cancer 76:1-6. 1998
    ..Further studies are necessary to detect the additional genetic alterations preceding the development of DNA aneuploidy...
  12. ncbi Comparison of flow cytometry and histology with mutational screening for p53 and Ki-ras mutations in surveillance of patients with long-standing ulcerative colitis
    K Holzmann
    Medizinische Klinik und Poliklinik, Abt Innere Medizin I, Universitatsklinikum Tubingen, Germany
    Scand J Gastroenterol 36:1320-6. 2001
    ..We evaluate the usefulness of screening for p53 and Ki-ras mutations in comparison with histological and flow cytometric findings...
  13. ncbi Telomerase activity in long-standing ulcerative colitis
    K Holzmann
    Department of Gastroenterology, University of Tuebingen, Germany
    Anticancer Res 20:3951-5. 2000
    ..These results show that telomerase activity might be used as a complementary marker to histology for the identification of patients with ulcerative colitis who are at an increased risk for neoplastic progression...
  14. ncbi [The role of oxaliplatin in the therapy for advanced colorectal carcinoma]
    O Nehls
    Abteilung Innere Medizin I mit den Schwerpunkten Gastroenterologie, Hepatologie und Infektiologie, Universitatsklinikum Tubingen, Germany
    Z Gastroenterol 39:1033-47. 2001
    ..In conclusion, the development of l-OHP has essentially increased the therapeutical possibilities of treatment for colorectal carcinoma...
  15. ncbi Serum and bile markers for cholangiocarcinoma
    Oliver Nehls
    Department of Internal Medicine I, University Hospital Tubingen, Germany
    Semin Liver Dis 24:139-54. 2004
    ..g., pancreatic polypeptide), and (epi-)genetic lesions (e.g., K- ras and p53 mutations, p16 (INK4a) or p14 (ARF) promoter hypermethylation). In this article we discuss these new potential tumor markers for the diagnosis of CC...
  16. ncbi Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma
    Oliver Nehls
    Department of Internal Medicine I, Eberhard Karls University Hospital of Tübingen, Tubingen, Germany
    Int J Radiat Oncol Biol Phys 61:85-91. 2005
    ..To determine the prognostic impact of BAX in correlation to its upstream effector p53 as well as clinicopathologic variables and patient outcome in preoperatively irradiated rectal carcinoma...
  17. ncbi A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer
    Christof Burkart
    Departments of Medical Oncology, Hematology, Immunology, Rheumatology, Pulmology, Medical Center II, Tubingen, Germany
    Anticancer Res 27:2845-8. 2007
    ..This study investigated the efficacy and toxicity of weekly single-agent irinotecan in patients with metastatic disease relapsing after cisplatin-based chemotherapy...
  18. ncbi Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients
    Tanja Spoettl
    Department of Internal Medicine I, University of Regensburg, Germany
    Inflamm Bowel Dis 13:727-32. 2007
    ..Soluble TNF receptors I and II (sTNF-RI + II) are released by proteolytic cleavage of the extracellular domains of these receptors. Soluble TNF-Rs act as TNF antagonists and can inhibit TNFalpha-mediated proinflammatory effects...
  19. ncbi Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
    Michael Stahl
    Department of Medical Oncology and Hematology, Kliniken Essen Mitte, Henricistr 92, D 45136 Essen, Germany
    J Clin Oncol 23:2310-7. 2005
    ..Combined chemoradiotherapy with and without surgery are widely accepted alternatives for the curative treatment of patients with locally advanced esophageal cancer. The value of adding surgery to chemotherapy and radiotherapy is unknown...
  20. ncbi Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract
    Mario Sarbia
    Institute of Pathology, Technical University, Munich, Germany
    Int J Cancer 111:224-8. 2004
    ..Our results suggest that hypermethylation of p16(INK4A) and APC are frequent findings in esophageal, cardiac and gastric ADC. Additionally, the data point to a tumor specific methylation pattern in upper gastrointestinal ADC...
  21. ncbi C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality
    Monika Bitzer
    Department of Pathology, Heinrich Heine Universitat, 40225 Dusseldorf, Germany
    Anticancer Res 23:1489-93. 2003
    ..The proto-oncogene c-myc is known to be involved in the regulation of proliferation, apoptosis and cell differentiation...